Table 1.
Characteristics of patients across treatment groups and baseline subsets
| Baseline subsets at randomization | DXMSoC, n = 239 N (%) |
DXM20, n = 234 N (%) |
|---|---|---|
| Age, years | ||
| < 70 | 144 (60.2) | 135 (57.7) |
| 70 | 95 (39.8) | 99 (42.3) |
| Time since symptoms onset, days | ||
| < 7 | 55 (23.1) | 52 (22.9) |
| 7 | 183 (76.9) | 175 (77.1) |
| Body Temperature, °C | ||
| < 38 | 186 (79.1) | 182 (78.1) |
| 38 | 49 (20.8) | 51 (21.9) |
| Inflammation syndromea | ||
| No | 26 (13.8) | 23 (13.2) |
| Yes | 162 (86.2) | 151 (86.8) |
| Missing | 51 | 60 |
| Age < 60 and no inflammation* | 3 (1.6) | 10 (5.7) |
| Age 60 and inflammation | 114 (60.6) | 122 (70.1) |
| Age < 60 and inflammation | 48 (25.5) | 29 (16.7) |
| Age 60 and no inflammation | 23 (12.2) | 13 (7.5) |
| Missing | 51 | 60 |
| CRP, mg/L | ||
| < 135 | 98 (49.7) | 98 (50.0) |
| 135 | 99 (50.3) | 98 (50.0) |
| Missing | 42 | 38 |
| Ferritin, μg/L | ||
| < 1120 | 76 (55.5) | 61 (44.2) |
| 1120 | 61 (44.5) | 77 (55.8) |
| Missing | 102 | 96 |
| Ferritin, μg/L | ||
| < 3150.29 | 123 (89.8) | 121 (87.7) |
| 3150.29 | 14 (10.2) | 17 (12.3) |
| Missing | 102 | 96 |
| D-Dimers, ng/mL | ||
| < 940 | 89 (46.4) | 103 (53.9) |
| 940 | 103 (53.6) | 88 (46.1) |
| Missing | 47 | 43 |
| Mode of oxygenation | ||
| O2 face mask | 48 (20.1) | 46 (19.7) |
| HFNO | 48 (20.1) | 41 (17.5) |
| CPAP | 47 (19.7) | 50 (21.4) |
| IMV | 96 (40.1) | 97 (41.4) |
| Invasive mechanical ventilation | ||
| No | 143 (59.9) | 137 (58.6) |
| Yes | 96 (40.1) | 97 (41.4) |
| SAPS II | ||
| < 33 | 113 (50.9) | 100 (47.6) |
| 33 | 109 (49.1) | 110 (52.4) |
| Other treatment of SARS-CoV-2 | ||
| Remdesivir | 61 (25.5) | 62 (26.5) |
| IL6 | 1 (0.4) | 4 (1.7) |
CRP C reactive protein, O2 oxygen, HFNO High-Flow Nasal Oxygen, CPAP Continuous Positive Airway Pressure, IMV invasive mechanical ventilation, IL6 interleukin 6, SAPS II Simplified Acute Physiology Score 2
aDefined as either ferritin level > 1000 μg/L or CRP > 100 mg/L